NONALCOHOLIC FATTY LIVER DISEASE AND ALBUMINURIA : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i7.1771Keywords:
Albuminuria, Kidney disease, Nonalcoholic fatty liver disease (NAFLD)Abstract
Background: The presence of fat storage in the liver that is larger than 5% of the liver's weight is diagnostic of nonalcoholic fatty liver disease (NAFLD), which can occur in the absence of excessive alcohol consumption or a secondary cause of liver illnesses. It is interesting to note that it has been hypothesised that NAFLD might be able to contribute to albuminuria by exacerbating the endothelial dysfunction that results from systemic inflammation.
Aim: This article examines the link between nonalcoholic fatty liver disease and albuminuria.
Methods: This study showed that it met all of the requirements by looking at the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. So, the experts could make sure that the study was as current as possible. The search method used a number of electronic reference databases, such as Pubmed and SagePub, to look for papers that were published between 2000 and 2023. We didn't look at review papers, articles that had already been published, or articles that were only half done.
Result: In the PubMed database, the results of our search brought up 89 articles, whereas the results of our search on SagePub brought up 33 articles. The results of the search conducted for the last year of 2013 yielded a total of 22 articles for PubMed and 16 articles for SagePub. In the end, we compiled a total of 17 papers, 12 of which came from PubMed and five of which came from SagePub. We included seven research that met the criteria.
Conclusion: Study has consistently shown that there is a correlation between NAFLD and albuminuria.
References
1. LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh K-L, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48(6):467–73.
2. Danford CJ, Lai M. NAFLD: a multisystem disease that requires a multidisciplinary approach. Frontline Gastroenterol. 2019;10(4):328–9.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
4. Lazarus J V, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78.
5. Mikolasevic I, Milic S, Wensveen TT, Grgic I, Jakopcic I, Stimac D, et al. Nonalcoholic fatty liver disease-A multisystem disease? World J Gastroenterol. 2016;22(43):9488.
6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–64.
7. Pais R, Maurel T. Natural history of NAFLD. J Clin Med. 2021;10(6):1161.
8. Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.
9. Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int. 2022;42(9):1955–68.
10. Macavei B, Baban A, Dumitrascu DL. Psychological factors associated with NAFLD/NASH: a systematic review. Eur Rev Med Pharmacol Sci. 2016;20(24).
11. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
12. Han E, Kim MK, Im S-S, Jang BK, Kim HS. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. J Diabetes Complications [Internet]. 2022;36(8):108253. Available from: https://www.sciencedirect.com/science/article/pii/S1056872722001623
13. Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci. 2019;16(2):285–91.
14. Choi JW, Oh IH, Lee CH, Park J-S. Is there a J-shaped relationship between the fatty liver index and risk of microalbuminuria in the general population? Clin Chim Acta. 2018;481:231–7.
15. Heidari Z, Gharebaghi A. Prevalence of non alcoholic fatty liver disease and its association with diabetic nephropathy in patients with type 2 diabetes mellitus. J Clin diagnostic Res JCDR. 2017;11(5):OC04.
16. Kasapoglu B, Turkay C, Yalc?n KS, Boga S, Bozkurt A. Increased microalbuminuria prevalence among patients with nonalcoholic fatty liver disease. Ren Fail. 2016;38(1):15–9.
17. Hamdy AA, El Shazly AK, Hazem EA, Hussein N, Hammouda AK, Abdul Aziz A. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. 2013;
18. Jenks SJ, Conway BR, Hor TJ, Williamson RM, McLachlan S, Robertson C, et al. Hepatic steatosis and non?alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabet Med. 2014;31(9):1039–46.
19. Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Muzica CM, Sfarti CV, et al. Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease. Can J Gastroenterol Hepatol. 2020;2020:3–5.
20. Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther. 2021;43(3):473–99.
21. Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(2):221–35.
22. Heda R, Yazawa M, Shi M, Satapathy SK, Bhaskaran M, Aloor FZ, et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 2021;27(17):1864–82.
23. Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol. 2015 Dec;418 Pt 1:55–65.
24. Zhang X, Ji X, Wang Q, Li JZ. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9(2):164–77.
25. Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Res A Clin Mol Teratol. 2015 Sep;103(9):787–93.
26. Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016;34(3):506–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
